12.50
-0.06 (-0.44%)
| 前收盘价格 | 12.55 |
| 收盘价格 | 12.45 |
| 成交量 | 230,689 |
| 平均成交量 (3个月) | 590,534 |
| 市值 | 935,181,952 |
| 价格/销量 (P/S) | 10.38 |
| 股市价格/股市净资产 (P/B) | 2.75 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业毛利率 | -121.73% |
| 营业利益率 (TTM) | -94.48% |
| 稀释每股收益 (EPS TTM) | -1.50 |
| 季度收入增长率 (YOY) | 170.30% |
| 总债务/股东权益 (D/E MRQ) | 5.68% |
| 流动比率 (MRQ) | 4.71 |
| 营业现金流 (OCF TTM) | -75.78 M |
| 杠杆自由现金流 (LFCF TTM) | -21.20 M |
| 资产报酬率 (ROA TTM) | -13.89% |
| 股东权益报酬率 (ROE TTM) | -29.80% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Zymeworks Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.25 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.19% |
| 机构持股比例 | 103.29% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Redmile Group, Llc | 31 Mar 2025 | 4,788,945 |
| Bnp Paribas Asset Management Holding S.A. | 31 Mar 2025 | 2,197,879 |
| 52周波幅 | ||
| 中 | 13.00 (4.04%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Jul 2025 | 13.00 (4.04%) | 保留 | 12.50 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合